| 货号 | 21578-5mg |
| 描述 | Eptifibatide is a potent glycoprotein IIB/IIIA antagonist (GPIIb/IIIa; Kd = 120 nM) that inhibits platelet aggregation.1,2 Eptifibatide prevents binding of the adhesion proteins fibrinogen and von Willebrand factor to GPIIb/IIIa on the surface of activated platelets to prevent aggregation and thrombus formation.3 It inhibits ADP-induced citrated blood aggregation (IC50 = 0.11-0.22 μg/mL) in vitroandin vivo(IC50 = 52 μg/mL in porcine plasma).1,4 Formulations containing eptifibatide have been used to reduce risk of thrombolysis in myocardial infarction in patients undergoing percutaneous coronary intervention.5 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Harder, S.,Klinkhardt, U.,Graff, J., et al. In vitro dose response to different GPIIb/IIIa-antagonists: Inter-laboratory comparison of various platelet function tests. Thromb. Res. 102(1), 39-48 (2001). 2.Moser, M.,Bertram, U.,Peter, K., et al. Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J. Cardiovasc. Pharmacol. 41(4), 586-592 (2003). 3.Scarborough, R.M. Development of eptifibatide. Am. Heart J. 138(6 Pt 1), 1093-1104 (1999). 4.Ciborowski, M., and Tomasiak, M. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets. Acta Pol. Pharm. 66(3), 235-242 (2009). 5.Zhou, X.,Wu, X.,Sun, H., et al. Efficacy and safety of eptifibatide versus tirofiban in acute coronary syndrome patients: A systematic review and meta-analysis. J. Evid. Based Med. 10(2), 136-144 (2017). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 832 |
| 分子式 | C35H49N11O9S2 |
| CAS号 | 188627-80-7 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |